Ironwood Pharma (IRWD) saw a positive improvement to its Relative Strength (RS) Rating on Monday, with an increase from 78 to 81.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD’s proprietary RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that shows how a stock’s price action over the trailing 52 weeks matches up against other publicly traded companies.
Decades of market research reveals that the best stocks tend to have an RS Rating of at least 80 as they begin their biggest price moves.
Ironwood Pharma is trying to complete a consolidation with a 14.31 entry. See if the stock can clear the breakout price in heavy volume.
Ironwood Pharma reported -25% earnings growth in the latest quarterly report. Revenue increased 0%.
The company earns the No. 44 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharmaceutcls (AMPH) and Corcept Therapeutics (CORT) are also among the group’s highest-rated stocks.